Get the Stockscreener App
12.28
4.96%
0.58
Zymeworks Inc. stock is traded at $12.28, with a volume of 951.13K.
It is up +4.96% in the last 24 hours and down -14.13% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$11.70
Open:
$11.9
24h Volume:
951.13K
Relative Volume:
1.96
Market Cap:
$854.40M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-8.1325
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
-6.83%
1M Performance:
-14.13%
6M Performance:
+0.82%
1Y Performance:
+13.60%
1-Day Range:
$11.82
$12.55
1-Week Range:
$10.96
$12.55
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
12.28 | 854.40M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Equities Analysts Issue Forecasts for Zymeworks Q1 Earnings - Defense World
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zymeworks (NYSE:ZYME) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Zymeworks (ZYME) with Outperform Recommendation - Nasdaq
Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13% - Simply Wall St
Zymeworks (NYSE:ZYME) Price Target Raised to $13.00 at HC Wainwright - Defense World
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings) - Benzinga
Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - Yahoo Finance
Citigroup Boosts Zymeworks (NYSE:ZYME) Price Target to $19.00 - Defense World
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 - Benzinga
Zymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call Transcript - Insider Monkey
Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights - Yahoo Finance
Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights By GuruFocus - Investing.com Canada
Zymeworks Reports 2024 Financial Results and Pipeline Progress - TipRanks
Zymeworks Achieves FDA Approval for Ziihera® - TipRanks
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates - MSN
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Zymeworks Q4 2024 sees modest revenue, stock dips - Investing.com UK
Zymeworks Q4 Net Loss Widens, Revenue Increases; Shares Fall After Hours -March 05, 2025 at 04:55 pm EST - Marketscreener.com
Zymeworks Inc Q4 2024 Earnings: EPS of -$0.31 and Revenue of $31 - GuruFocus.com
Zymeworks shares fall as Q4 earnings miss expectations By Investing.com - Investing.com Canada
Zymeworks shares fall as Q4 earnings miss expectations - Investing.com India
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
How Will Zymeworks' FDA Win for Ziihera Impact Its $122M Annual Loss? - StockTitan
Rhumbline Advisers Buys 15,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Zymeworks (ZYME) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Zymeworks Inc.'s (NASDAQ:ZYME) Business Is Yet to Catch Up With Its Share Price - Simply Wall St
Zymeworks Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsZYME - ACCESS Newswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration - Wahanariau
Zymeworks Achieves $14 Million in Milestone Payment From GSK Partnership -February 26, 2025 at 09:06 am EST - Marketscreener.com
Zymeworks Secures $14 Million Milestone from GSK Collaboration - TipRanks
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Inc. Announces Participation in Upcoming Investor Conferences in March 2025 - Nasdaq
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Can Zymeworks' March Conference Circuit Signal New Clinical Progress? - StockTitan
MarketsMedicine Hat News - Financial Content
Did Zymeworks Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateZYME - ACCESS Newswire
Zymeworks Inc. (NYSE:ZYME) Receives $19.17 Average Price Target from Brokerages - MarketBeat
Brokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $19.17 - Defense World
Zymeworks Inc. Announces Appointment of Oleg Nodelman to the Board of Directors - Marketscreener.com
Zymeworks Welcomes Oleg Nodelman to Board of Directors - TipRanks
Zymeworks Announces Appointment Of Oleg Nodelman To Board Of Directors -February 18, 2025 at 06:18 am EST - Marketscreener.com
Zymeworks Inc. Appoints Oleg Nodelman to Board of Directors as Part of Ongoing Board Renewal Process - Nasdaq
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors - GlobeNewswire
Major Strategic Move: Zymeworks Adds Largest Shareholder's Founder to Board, Signaling Growth Focus - StockTitan
Zymeworks BC Inc (ZYME) can make a big difference with a little luck - SETE News
Zymeworks (NYSE:ZYME) Stock Price Down 5.4%Should You Sell? - MarketBeat
Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs - MarketBeat
Zymeworks to Announce 2024 Financial Results and Host Corporate Update - TipRanks
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 - The Korea Bizwire
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):